However, despite recent advances in glioblastoma (GBM), where intrathecal infusion of the IL13RA2/EGFRvIII dual targeting “OR gate” CAR-T is showing very encouraging signs of clinical activity (71) (NCT05168423), “OR gate” approaches are unlikely to become broadly applicable in other solid tumor types given that achieving a safe therapeutic index with a TCE or CAR-T against a single TAA is already a significant hurdle; therefore, for solid tumor indications alternative logic gated strategies are more likely to be successful and are starting to take shape. This evidence concerns the gene IL13RA2 and glioblastoma.